Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report

Figure 1 Timeline of treatment course of patient with malignant pleural mesothelioma. PFS: Progression-free survival; SRS: Stereotactic radiosurgery.

Figure 2 Representative images. A: Representative images of computed tomography images showing right pleural occupation with effusion; B: Representative images of pleural mesothelioma tissue stained with hematoxylin and eosin.

Figure 3 Computed tomography examination. A: Response of the main lesion estimated by computed tomography. The pleural mass significantly progressed after one cycle of carboplatin plus pemetrexed (A-II). Partial response after two (A-III) and four (A-IV) cycles of pembrolizumab and bevacizumab with chemotherapy; B: Image of immunerelated pneumonia (IRP) before and after immunotherapy. B-I: IRP occurred after five cycles of Immune checkpoint inhibitor. B-II: One week after administration of methylprednisolone; B-III: 2 wk after administration of methylprednisolone; B-IV: IRP decreased after 1 mo of methylprednisolone therapy.